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Abstract
Purpose The treatment of recurrent ovarian carcinoma
(ROC) has become increasingly oriented according to the
therapy principles of a chronic disease. We evaluated
whether it is justiWable to also apply this concept to the
treatment of platinum resistant patients with their known
poor prognosis and short overall survival (OS).
Methods We analyzed the overall courses of 85 unse-
lected ROC patients and deWned the following groups: A,
platinum resistant patients (n = 39); subgroup A.1, those
who received no or at maximum one line of palliative che-
motherapy (n = 15, 38.5%); subgroup A.2, those who
received ¸ two therapy lines (n = 24, 61.5%); B, platinum
sensitive patients, n = 46.
Results Group A had signiWcantly lower OS than group B
(median: 16 vs. 25 months; p = 0.019). Group A.1 had sig-
niWcantly worse outcome compared to group A.2 (median:
5 vs. 21.5 months; p < 0.001). The comparison between
study group A.2 and group B showed comparable survival
rates (p = 0.738). Considering only the patients who had
completed treatment courses, the median number of therapy
lines administered was higher in group A.2 than in group B
(4 vs. 3; p = 0.008).
Conclusions There is not only the known dichotomy
between platinum sensitive and resistant ROC patients, but
rather also within the platinum resistant subgroup itself.
There is a considerably large subgroup of platinum resistant
patients who will subsequently enter a phase where multi-
ple treatment programs will be considered and adminis-
tered. These patients have similar survival rates compared
to those from the platinum sensitive patient group and the
therapy principles of a chronic disease are applicable.
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Introduction
The majority of women with ovarian carcinoma are diag-
nosed with advanced-stage disease. Despite continuing
improvements in Wrst-line treatment (the current standard
is platinum-based chemotherapy regimens), most patients
relapse and die of the disease within 5 years [1]. Cur-
rently, second-line therapy hardly provides a realistic
chance of a cure; thus, the goals of treatment are diVerent
from Wrst-line chemotherapy and include prolonging sur-
vival, improving cancer-related symptoms, delaying the
development of symptoms, and improving quality of life
[2].
Patients with recurrent ovarian carcinoma (ROC) are
generally categorized into two primary groups: platinum-
sensitive, in which the disease recurs after 6 months from
the time of Wrst-line platinum-based chemotherapy, and
platinum resistant, in which the progression-free survival
(PFS) is less than 6 months from completion of treatment.
This well-established dichotomy reXects the expected
eYcacy of further palliative systemic therapy options.
While platinum sensitive patients experience response rates
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platinum resistant patients have demonstrated response
rates of usually <20% and an OS of <12 months [3–5].
In the last decade, ROC has become increasingly viewed
as a chronic disease process [2, 6, 7]; the choice of systemic
palliative therapy options takes this concept increasingly
into account [8]. The goal of this study was to demonstrate
whether it is justiWable to also apply this concept to the
treatment of platinum resistant patients with their known
poor prognosis and short OS. In order to address this issue,
we analyzed the overall courses of an unselected popula-
tion-based study cohort of patients whose ROC was diag-
nosed during a 10 year period (1997–2006).
Patients and methods
The Basel Ovarian Carcinoma Database is comprised of
extensive data concerning clinical, histo- and pathomorpho-
logic features and treatment characteristics of all patients
whose primary epithelial ovarian cancer was diagnosed in
the canton Basel-Stadt (Basel, Switzerland) since 1990. For
this study, we considered the data from patients whose
ROC was initially diagnosed from 1997 to 2006 and who
were treated postoperatively with at least three cycles of
platinum-based chemotherapy as Wrst-line treatment
(median number of cycles: 6, range 3–11). Since the use of
palliative chemotherapy options was a crucial factor evalu-
ated in this study, we did not include patients for whom the
choice of possible treatment options were limited by
advanced age (older than 75 years).
Ultimately, 85 patients were analyzed in this study. The
clinicopathologic, treatment and outcome characteristics of
these patients are summarized in Tables 1 and 2. Most of
the patients had FIGO (International Federation of Gyne-
cology and Obstetrics) stages I–III at initial diagnosis
(n = 77). In the remaining eight patients who were classi-
Wed as having stage IV disease, the grouping into this stage
was based only on the diagnosis of pleural involvement
and/or liver parenchymal metastases; patients with other
distant metastases (lesions beyond the abdominal cavity)
were excluded from analysis. Of the entire study cohort, 39
patients had a PFS <6 months after completion of Wrst-line
chemotherapy and were therefore considered as being plati-
num resistant (study group A). 46 patients who were plati-
num sensitive (PFS > 6 months) comprised study group B.
No patients were lost to follow-up and we could provide
complete information regarding palliative therapy course
(number of chemotherapy lines and the agents adminis-
tered) and outcome for all patients. Information concerning
palliative treatment was obtained from 11 oncologic units
in Switzerland, as well as neighboring regions in Germany
and France. The patients were followed until death or,
if they remained alive and disease free, for a minimum of
24 months (conclusion of the data collection in July 2008).
Overall survival was deWned as the interval from the date of
diagnosis of ROC to the date of death. In this manner, the
recurrent disease-speciWc survival was calculated.
One patient in study group B had isolated brain metasta-
ses, i.e., no recurrent disease in the abdominal region, and
received only radiotherapy. All other patients included in
the study had recurrence in abdominal sites as a manifesta-
tion of recurrent disease. The majority of the patients died
of ROC (group A: n = 38, 97.4%; group B: n = 40, 87.0%).
One patient in group A and six patients in group B were
alive at the conclusion of the observation period; four
patients in group B, as well as the one patient in group A,
had ongoing palliative therapies. In two further patients in
group B, localized recurrent disease was diagnosed. In one
case, a 47-year-old woman had a recurrent tumor mass in
the pelvis, which was surgically removed (no postoperative
residual disease), and postoperatively received a second-
line chemotherapy with six cycles of carboplatin and paclit-
axel. The other patient (age, 74 years) had a histologically
proven recurrence as a Wxed pelvic mass eroding the vagi-
nal mucosa. This 74-year-old patient was treated with six
cycles of carboplatin as monotherapy. These two patients
have experienced a long asymptomatic period (49 and
55 months, respectively) up until the conclusion of the
observation period and could be even considered as poten-
tially cured.
It was the goal of our study to evaluate whether the ther-
apy principles of a chronic disease can also be applied in
platinum resistant patients. An important feature of a
chronic disease therapy situation is that, besides demonstrat-
ing a long enough survival time to be considered as chronic,
the ability to administer antineoplastic therapy at all needs to
be possible. Therefore, we further subdivided the study
group of the platinum resistant patients as follows:
Group A.1 patients who received no antineoplastic sys-
temic treatment or at maximum one line of
palliative chemotherapy, n = 15 (38.5%).
Group A.2 patients who received ¸two therapy lines,
n = 24 (61.5%).
The study design and data collection methods were
approved by our institutional review board.
Statistical analysis
To predict the OS with ROC, we used the Kaplan–Meier
method. Patients who were alive at the conclusion of the
observation period were censored in the statistical anal-
yses. Statistical diVerences between groups in terms of
survival curves were analyzed using the log rank test. To123
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between two groups, the nonparametric exact Wilcoxon
test was performed.
To predict how the platinum resistant patients fell into
the subgroups A.1 or A.2, multiple logistic regression was
performed. Independent predictors were age, relapse-free
period, and the amount of residual disease after cytoreduc-
tive surgery.
A p value <0.05 was considered to be signiWcant. Odds
ratio (OR) and the corresponding 95% conWdence interval
(CI) were reported. For continuous variables, ORs were
calculated as the ratio from the third to the Wrst quantile of
the corresponding distribution. Statistical analyses were
performed with R Development Core Team software, ver-
sion 2.7.0 (Vienna, Austria).
Results
A comparison between both study groups showed that
group A had signiWcantly lower OS than platinum sensitive
patients (Fig. 1; p = 0.019). The 1-year adjusted survival
rate was 53.9% for group A compared to 82.6% for group
Table 1 Clinicopathologic and 
outcome characteristics of 85 
patients with recurrent ovarian 
carcinoma Wrst diagnosed 
1997–2006
Variable Group A Group B
Entire group, n (%) 39 (100) 46 (100)
FIGO stage at initial diagnosis
Stage I 3 (7.7) 2 (4.3)
Stage II 3 (7.7) 6 (13.1)
Stage III 27 (69.2) 36 (78.3)
Stage IV 6 (15.4) 2 (4.3)
Histologic subtype
Serous 29 (74.4) 41 (89.1)
Mucinous 4 (10.2) –
Endometriod 3 (7.7) 4 (8.7)
Clear-cell 3 (7.7) 1 (2.2)
Residual disease after cytoreductive surgery
No macroscopic residual disease 10 (25.6) 26 (56.5)
Residual disease <1 cm 9 (23.1) 10 (21.7)
Residual disease 1–2 cm 9 (23.1) 6 (13.1)
Residual disease >2 cm 10 (25.6) 4 (8.7)
Unknown amount of residual disease 1 (2.5) –
Postoperative platinum-based CT
Platinum monotherapy 9 (23.1) 8 (17.4)
Platinum + taxane 23 (59.0) 25 (54.3)
Platinum + cyclophosphamide 6 (15.4) 12 (26.1)
Platinum + other CT agent 1 (2.5) 1 (2.2)
Age at diagnosis of recurrent disease
Mean (range) 57.3 years (29–75) 59.2 years (33–75)
Outcome status
Died of ovarian cancer 38 (97.4) 40 (87.0)
Died of other causes – –
Alive (ongoing therapy with evident disease) 1 (2.6) 4 (8.7)
Alive (no evidence of disease >48 months) – 2 (4.3)
Group A, platinum resistant pa-
tients (n = 39); Group B, plati-
num sensitive patients (n = 46)
CT chemotherapy, FIGO Inter-
national Federation of Gynecol-
ogy and Obstetrics
Table 2 Number of therapy lines received by patients who died of
recurrent ovarian carcinoma
Group A, platinum resistant patients (n = 38); Group B, platinum
sensitive patients (n = 40)
Group A Group B
Total no. of patients, n (%) 38 (100) 40 (100)
No systemic therapy 5 (13.2) 2 (5.0)
1 therapy line 10 (26.3) 5 (12.5)
2 therapy lines 4 (10.5) 12 (30.0)
3 therapy lines 6 (15.8) 9 (22.5)
4 therapy lines 7 (18.4) 7 (17.5)
5 therapy lines 3 (7.9) 3 (7.5)
6 therapy lines 2 (5.3) 1 (2.5)
7 therapy lines – 1 (2.5)
9 therapy lines 1 (2.6) –123
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rates were 5.1 and 8.9%, respectively. The median OS time
was 16 months in group A and 25 months in group B.
If one subdivides the study group with platinum resistant
patients further according to the number of therapy lines
administered in the palliative setting, one Wnds again a clear
dichotomy. Patients who received no or maximal one ther-
apy line (group A.1) have signiWcantly worse outcome
compared to group A.2, which was comprised of patients
who received ¸2 therapy lines (Fig. 2; p < 0.001). In group
A.1, no patient survived longer than 10 months. In group
A.2, the 1-year adjusted survival rate was 87.5%, while the
3-year rate was 20.8% and the 5-year rate was 8.3%. The
median OS time was 5 months in group A.1 and
21.5 months in group A.2. In a multivariate analysis of the
patients of study group A, a short relapse free period was a
signiWcant factor for the patients that eventually fell into
sub-study group A.1 (OR, 5.75; 95% CI, 1.12–29.54;
p = 0.036). Age (OR, 0.39; 95% CI, 0.12–1.26; p = 0.11)
and residual disease after cytoreductive surgery (OR, 4.26;
95% CI, 0.68–26.63; p = 0.12) were shown not to be sig-
niWcant variables.
The comparison between study group A.2 and platinum
sensitive patients showed comparable survival rates (Fig. 2,
p = 0.738). Considering only the patients who ultimately
died of their disease, i.e., who had completed treatment
courses, the median number of therapy lines administered
was higher in the platinum resistant subgroup than in the
platinum sensitive one (group A.2: 4 lines vs. group B: 3
lines; p = 0.008).
Discussion
In the last decade, ROC has become increasingly viewed as
a chronic disease process [2, 6–8]. Chronic diseases are by
deWnition long-lasting or recurrent and require a long
period of treatment, supervision, observation or care; they
are caused by nonreversible pathological alterations, leave
residual disability, and can be altered but not be cured by
various therapies [9, 10]. In any case, one main therapeutic
goal in the management of chronic diseases, which can also
be applied to the treatment of ROC, is fulWlled when a dis-
ease which requires periodic chemotherapy to control pro-
gressive course and symptoms can be treated with a
strategy that permits stabilization with treatment regimens
that have limited cumulative toxicity [2, 8].
Undoubtedly, through the introduction of a new genera-
tion of cytotoxic agents with safer proWles (above all, lipo-
somal doxorubicin, gemcitabine and topotecan) and of
course, through considerable advances in supportive care,
the therapy concepts of chronic disease can be better imple-
mented today compared to earlier times. We deliberately
chose our study period to ensure that the above mentioned
new drugs were available on the market. In a recent study,
we could demonstrate that oncologists, using the currently
available agents, are increasingly able to accordingly adjust
the therapies in ROC patients with this principle in mind
(e.g., administration of signiWcantly fewer combination
therapies with more favorable toxicity proWles) [8].
There is no generally accepted deWnition as to how long a
disease must last in order to be considered as chronic. In the
case of rapidly progressive disease which leads to death
within a few months, this is surely not justiWed. Therefore, it
must be questioned whether the term chronic disease is
appropriate in association with platinum resistant ROC.
Despite numerous chemotherapeutic strategies (overview in
[11]), the poor prognosis has remained unchanged for these
patients. Rocconi et al. [12] evaluated the cost-eVectiveness
Fig. 2 Overall survival among 85 patients with recurrent ovarian car-
cinoma. Group A.1, platinum resistant patients who received no sec-
ond-line chemotherapy or at maximum one line of palliative treatment
(n = 15); Group A.2, platinum resistant patients who received ¸2
palliative chemotherapy lines (n = 24); Group B, platinum sensitive
patients (n = 46)
Fig. 1 Overall survival among 85 patients with recurrent ovarian car-
cinoma. Group A, platinum resistant patients (n = 39); Group B, plati-
num sensitive patients (n = 46)123
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provocatively demonstrated that best supportive care was
the only cost-eVective strategy for these patients.
Our study demonstrates that there is not only a dichot-
omy between platinum sensitive and resistant ROC
patients, but rather also within the platinum resistant sub-
group itself. Some of the patients experienced a rapidly
progressive course of disease. These patients quickly
showed that they do not respond well to further chemother-
apy or reject further treatment, due to shock and disappoint-
ment with the recently completed ineVective Wrst-line
therapy and its toxicities. For these patients, who have a
median survival less than 6 months, the term chronic dis-
ease is surely not appropriate. On other hand, there is a con-
siderably large subgroup of platinum resistant patients who
will subsequently enter a phase where multiple treatment
programs will be considered and administered. These
patients have similar survival rates compared to those from
the platinum sensitive ROC patient group. In these patients,
as demonstrated above, the therapy principles of a chronic
disease are applicable.
In general, we think that in platinum resistant ROC
patients, therapeutic nihilism is not justiWed. The substan-
tial percentage of patients with ovarian cancer who wish to
continue active anticancer treatment despite the develop-
ment of platinum- and taxane-resistant disease should be
encouraged by their oncologists to begin or to continue sec-
ond line therapies. The choice of treatment options will
depend on any given patient’s clinical situation and her
ability and readiness to tolerate the known side eVects of
the selected drug.
Many authors have suggested that, from a clinical
perspective, the deWnitions of platinum sensitivity and
resistance may be arbitrary [2, 13, 14]. The principle of
second-line therapy is that if the treatment is successful,
patients will eventually have another recurrence and
undergo additional rounds of therapy. In this sense, we also
think that platinum-sensitive and resistant diseases are not
necessarily diVerent entities in terms of the concept of a
chronic disease.
The limitations of our study, however, must be consid-
ered. First, our study comes from a single region of a small
country with a high socioeconomic status. All inhabitants
of Switzerland have universal access to health care and free
access to all prescribed and approved drugs. These facts
must be considered while interpreting our results. Sec-
ondly, our study analyzes retrospective data. One has to
realize, however, that prospective randomized trials are
unsuitable for addressing the topic of our study. There
exists a vast amount of literature concerning the systemic
therapy of ROC (overview in [1, 2, 7, 13–16], particularly
for platinum resistant disease in [11]). However, nearly all
clinical trials concentrate only on the feasibility and impact
of deWned therapy options, usually in second line treatment
situations early after the initial diagnosis of ROC. They
focus on the evaluation and comparison of particular anti-
neoplastic agents and drugs, but in doing so, can only eval-
uate particular therapy options in pre-selected groups of
patients in certain situations. Thus, their ability to describe
the overall course of recurrent disease is limited. Only a
few trials have evaluated the clinical eYcacy of third-,
fourth- or Wfth-line therapies [17]; due to the heterogeneous
composition of these study groups of heavily pretreated
women, insights from therapy over the entire disease course
is often only interpretable in a limited manner. In order to
evaluate the treatment course of a chronic disease, how-
ever, it is essential to give an overview of the entire course
of the disease. In our opinion, this is only achievable
through the analysis of retrospective data of a population-
based cohort, as done in our study.
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